I begge forsøg oplevede patienter med sekundær progressiv dissemineret sklerose en reduktion i hyppighed (30%) af kliniske relapser.
In both trials secondary progressive multiple sclerosis patients receiving Extavia showed a reduction in frequency (30%) of clinical relapses.